US FDA EMDAC backs Novartis Cushing's drug, despite liver, hyperglycemia concerns
This article was originally published in Scrip
Executive Summary
A federal panel of advisers overwhelmingly supported the approval of Novartis’ experimental drug Signifor (pasireotide) as a treatment for patients with Cushing's disease who require medical therapeutic intervention.